CJC 1295 NO DAC IPAMORELIN

Multi-Buy Savings — Add 2+ products to save 10% automatically. Add 3+ to save 15%. Applied at checkout.

CJC-1295 (No DAC) + Ipamorelin is a research peptide combination pairing a GHRH analogue with a selective GHRP to produce synergistic growth hormone secretagogue activity. CJC-1295 (No DAC; CAS 863288-34-0) is a 30-amino-acid GHRH analogue studied for its ability to stimulate pulsatile GH release from pituitary somatotrophs without drug affinity complex (DAC) extension. Ipamorelin (CAS 170851-70-4) is a highly selective pentapeptide GHRP that acts on the ghrelin/GHS-R1a receptor to potentiate GH secretion with minimal off-target effects on cortisol or prolactin.

The combination is studied in preclinical endocrinology research for its ability to model pulsatile GH physiology, investigate somatotroph function, and study downstream IGF-1 and metabolic signalling. The two compounds act via distinct but complementary receptor pathways (GHRH-R and GHS-R1a), making their combination a useful dual-agonist research tool.

CJC-1295 CAS: 863288-34-0  ·  Ipamorelin CAS: 170851-70-4  ·  Purity: ≥99% HPLC (each component)  ·  Format: Lyophilised powder blend  ·  Storage: −20 °C

Research Areas: Pulsatile GH release · GHRH-R / GHS-R1a dual agonism · Endocrine signalling · IGF-1 pathway · Pituitary somatotroph function · Metabolic research

Research Literature:
• Ipamorelin: first selective growth hormone secretagogue (PMID 9849822)
• PK/PD modelling of ipamorelin in human volunteers (PMID 10496658)
• PubMed: CJC-1295 + Ipamorelin research literature →

Research Use Only. Supplied strictly for in vitro laboratory research by qualified professionals. Not for human or veterinary administration. Not evaluated by the MHRA or FDA for therapeutic use. Researchers must comply with the Human Medicines Regulations 2012 and all applicable institutional guidelines. Peptide Biosciences accepts no liability for use outside a controlled research context.